Cessation of Somatostatin Analogues After PRRT in Mid, Hind-Gut and Pancreatic Neuroendocrine Tumours
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
Neuroendocrine tumours (NETs) are slow growing cancers, which commonly present as metastatic incurable disease. Some neuroendocrine tumours, termed functional NETs, overproduce hormones which result in a variety of symptoms. However, approximately 75% of NETs are considered non-functional meaning that they do not result in hormone overproduction. The main treatment for both functional and non-functional NETs is somatostatin analogues (SSA, a type of inhibitory hormone). These drugs slow tumour growth and reduce hormone production. Over time, the majority of patients will experience tumour growth despite treatment with SSA therapy. When this occurs, the addition of Peptide Receptor Radionuclide Therapy (PRRT, a type of targeted radiotherapy) in combination with ongoing SSA therapy is given. However, it is not known if continuing SSA therapy after commencement of PRRT is beneficial or not. The aim of this study is to estimate the outcomes of patients with grade 1 and 2 well differentiated mid, hind-gut or pancreatic neuroendocrine tumours who have progressed on SSA therapy and receive subsequent PRRT with or without concurrent SSA.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek powyżej 18 lat
- •Nowotwór neuroendokrynny ze zmianami przerzutowymi, nieoperowalny, rosnący mimo poprzedniego leczenia
- •Możliwość mierzenia guza w badaniach obrazowych (CT/MRI)
- •Otrzymywanie leczenia hormonalnego przez co najmniej 12 tygodni przed włączeniem do badania
- •Potwierdzenie receptorów somatostatyny w badaniu PET
- •Terapia PRRT uznana za najlepszy następny krok leczenia
- •Zadowalająca funkcja nerek, wątroby i układu krwiotwórczego
- •Przewidywana długość życia co najmniej 12 miesięcy
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- September 10, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (17)
Royal North Shore Hospital
Sydney, Australia
Wollongong Hospital
Wollongong, Australia
Royal Brisbane and Womens Hospital
Brisbane, Australia
Cairns Hospital
Cairns, Australia
Toowoomba Hospital
Toowoomba, Australia
The Queen Elizabeth Hospital
Adelaide, Australia
Peter MacCallum Cancer Centre
Melbourne, Australia
Kalgoorlie Health Campus
Kalgoorlie-Boulder, Australia
Fiona Stanley Hospital
Perth, Australia
Cross Cancer Institute
Edmonton, Canada
BC Cancer Agency, Vancouver Cancer Centre
Vancouver, Canada
London Health Sciences Centre Research Institute (LHSCRI)
London, Canada
Ottawa Hospital Research Institute
Ottawa, Canada
University Health Network Princess Margaret Cancer Centre
Toronto, Canada
Odette Cancer Centre Sunnybrook Health Sciences Centre
Toronto, Canada
Allan Blair Cancer Centre
Regina, Canada
Saskatoon Cancer Centre
Saskatoon, Canada
Trial contact
Julia Kuszewski
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 9/11/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.